A report made available this week by the U.S. Government Accountability Office (GAO) shows that the Food and Drug Administration (FDA) needs to address some serious cybersecurity weaknesses that expose industry and public health data.
An audit conducted by the GAO between February 2015 and August 2016 revealed several problems that put the confidentiality, integrity, and availability of the FDA’s systems at risk.
The GAO’s analysis targeted seven of the FDA’s 80 systems. The machines covered by the audit receive and process sensitive drug information and are essential to the agency’s mission. Since they have a Federal Information Processing Standard of moderate or high impact, if the systems or their information is compromised, it could have a serious or catastrophic impact on the organization.
A total of 87 weaknesses have been identified by GAO, including failure to protect network boundaries, identify and authenticate users, restrict user permissions, encrypt sensitive data, monitor system activity, and conduct physical security reviews.
For instance, the FDA’s internal network was not isolated from the network of the contractor in charge of the agency’s public website. The internal network was also accessible from one of the organization’s untrusted networks.
Another example refers to the FDA’s failure to implement strong password controls, including passwords that remained unchanged for several years, weak credentials and default settings.
As for authorization-related concerns, the GAO discovered that hundreds and even thousands of user accounts had unnecessary or uncontrolled access to file shares. The audit also revealed that sensitive data, including passwords, were not properly encrypted.
The FDA did not properly audit and monitor its systems, which could allow malicious actors to remain undetected for extended periods of time. The GAO pointed out that the agency did not always retain audit logs, and it failed to preserve evidence related to a 2013 security breach that resulted in an external attacker gaining access to sensitive user account information.
“FDA has taken steps to safeguard its systems that receive, process, and maintain sensitive data by, for example, implementing policies and procedures for controlling access to and securely configuring those systems. However, a significant number of weaknesses remain in technical controls — including access controls, change controls, and patch management — that jeopardize the confidentiality, integrity, and availability of its systems,” the GAO said in its report.
One of the causes of weak security controls, according to the GAO, is the lack of a properly implemented agency-wide information security program as required by federal laws. These laws require government organizations to implement risk assessments, incident response procedures, regular testing of security controls, reviews and updates for security policies and procedures, vulnerability patching mechanisms, and security training.
The GAO has made over a dozen recommendations for the implementation of an agency-wide information security program and 166 recommendations on addressing specific problems.
Related: Huge US Facial Recognition Database Flawed
Related: DHS’s Einstein Security System Has Limited Capabilities
Related: Internet Connectivity Could Expose Aircraft Systems to Cyberattacks
